GGrantIndex
← Leaderboards

Julie Magarian Blander

Weill Medical Coll Of Cornell Univ

$17,921,173
Attributed
$18,120,642
Total exposure
15
Grants
15
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.3M · FY200725
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$19,436,055 · 16

By mechanism

R01$13,519,730 · 7
U54$1,952,761 · 2
R21$1,797,313 · 4
P01$1,742,501 · 2
R56$423,750 · 1

Top collaborators

Most similar at Weill Medical Coll Of Cornell Univ

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsPathway InteractionsImmunityResponseSignal TransductionPathogenMicrobialAntigensDesignTissuesImmuneMediatingToll-Like ReceptorsProteinsInfectionImmune SystemDendritic CellsCd4 Positive T LymphocytesReceptor SignalingMolecularApoptoticImmune ResponsePeptidesViral

Grant awards (45)

CAP-IT Center for LNP RNA Immunoprevention$1,315,413
U54 · FY2025 · CA
Toll-like receptor control of endocytic antigen cross-presentation$675,627
R01 · FY2025 · AI · contact PI
Mobilizing TAP-independent CD8 T cells through non-canonical cross-presentation$656,593
R01 · FY2025 · AI · contact PI
Lynch Vaccine$637,348
U54 · FY2025 · CA · contact PI
Mobilizing TAP-independent CD8 T cells through non-canonical cross-presentation$676,900
R01 · FY2024 · AI · contact PI
Toll-like receptor control of endocytic antigen cross-presentation$675,627
R01 · FY2024 · AI · contact PI
Modulating XIAP for the Treatment of Inflammatory Bowel Disease$173,438
R21 · FY2024 · AI · contact PI
Mobilizing TAP-independent CD8 T cells through non-canonical cross-presentation$676,900
R01 · FY2023 · AI · contact PI
Toll-like receptor control of endocytic antigen cross-presentation$675,627
R01 · FY2023 · AI · contact PI
Modulating XIAP for the Treatment of Inflammatory Bowel Disease$225,500
R21 · FY2023 · AI · contact PI
Toll-like Receptor Control of MHC Class I Endocytosis$211,875
R21 · FY2023 · AI · contact PI
Toll-like Receptor Control of MHC Class I Endocytosis$254,250
R21 · FY2022 · AI · contact PI
Innate and Adaptive Immune Consequences of Necroptosis$211,875
R21 · FY2021 · AI · contact PI
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines$419,267
R01 · FY2020 · AI · contact PI
Non-Canonical Cross-presentation in Dendritic Cells Upon TAP Blockade$414,928
R01 · FY2020 · AI · contact PI
Role of apoptosis in the intestinal epithelium during homeostasis and disease$381,375
R01 · FY2020 · DK · contact PI
Innate and Adaptive Immune Consequences of Necroptosis$254,250
R21 · FY2020 · AI · contact PI
Non-Canonical Cross-presentation in Dendritic Cells Upon TAP Blockade$419,267
R01 · FY2019 · AI · contact PI
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines$419,267
R01 · FY2019 · AI · contact PI
Role of apoptosis in the intestinal epithelium during homeostasis and disease$381,375
R01 · FY2019 · DK · contact PI
Non-Canonical Cross-presentation in Dendritic Cells Upon TAP Blockade$419,267
R01 · FY2018 · AI · contact PI
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines$419,267
R01 · FY2018 · AI · contact PI
Role of apoptosis in the intestinal epithelium during homeostasis and disease$381,375
R01 · FY2018 · DK · contact PI
Non-Canonical Cross-presentation in Dendritic Cells Upon TAP Blockade$419,267
R01 · FY2017 · AI · contact PI
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines$419,267
R01 · FY2017 · AI · contact PI
Role of apoptosis in the intestinal epithelium during homeostasis and disease$381,375
R01 · FY2017 · DK · contact PI
Non-Canonical Cross-presentation in Dendritic Cells Upon TAP Blockade$420,670
R01 · FY2016 · AI · contact PI
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines$419,267
R01 · FY2016 · AI · contact PI
Control of protective immunity by innate pathways sensing bacterial viability$423,750
R01 · FY2015 · AI · contact PI
The Antigen Specificity of TH17 Cells to Pathogen and Epithelium$362,001
P01 · FY2015 · DK · contact PI
Control of protective immunity by innate pathways sensing bacterial viability$423,750
R01 · FY2014 · AI · contact PI
The Antigen Specificity of TH17 Cells to Pathogen and Epithelium$362,001
P01 · FY2014 · DK · contact PI
Control of protective immunity by innate pathways sensing bacterial viability$398,325
R01 · FY2013 · AI · contact PI
The Antigen Specificity of TH17 Cells to Pathogen and Epithelium$294,497
P01 · FY2013 · DK · contact PI
Control of protective immunity by innate pathways sensing bacterial viability$423,750
R01 · FY2012 · AI · contact PI
The Regulatory Control Mechanisms of Cross-presentation by Toll-like Receptors$415,317
R01 · FY2012 · AI · contact PI
The Antigen Specificity of TH17 Cells to Pathogen and Epithelium$362,001
P01 · FY2012 · DK · contact PI
The Regulatory Control Mechanisms of Cross-presentation by Toll-like Receptors$415,317
R01 · FY2011 · AI · contact PI
The Antigen Specificity of TH17 Cells to Pathogen and Epithelium$362,001
P01 · FY2011 · DK · contact PI
The Regulatory Control Mechanisms of Cross-presentation by Toll-like Receptors$419,513
R01 · FY2010 · AI · contact PI
Innate Immune Sensing of Microbial Viability$254,250
R21 · FY2010 · AI · contact PI
The Regulatory Control Mechanisms of Cross-presentation by Toll-like Receptors$423,750
R01 · FY2009 · AI · contact PI
Innate Immune Sensing of Microbial Viability$211,875
R21 · FY2009 · AI · contact PI
The Regulatory Control Mechanisms of Cross-presentation by Toll-like Receptors$423,750
R01 · FY2008 · AI · contact PI
The Regulatory Control Mechanisms of Cross-presentation by Toll-like Receptors$423,750
R56 · FY2007 · AI · contact PI